Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Encapsulated Rapamycin

Small molecule · Inhibitor of mammalian target of rapamycin (MTOR) · developed by Biodexa Pharmaceuticals

Phase 2 Most advanced trial

BDRX Developer

1 Registered trials

What is Encapsulated Rapamycin?

Encapsulated rapamycin is an orally administered nanoparticle formulation of the macrolide rapamycin designed for tumor-targeted delivery. It binds FKBP-12 to form a complex that inhibits mTOR kinase, suppressing mTORC1 activity and modulating CD8 T cells and NK cells. The encapsulation improves bioavailability and allows lower dosing. It is studied in familial adenomatous polyposis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: eRapa; Encapsulated sirolimus
Drug type: Small molecule
Targets: mammalian target of rapamycin (MTOR), FK Binding Protein-12 (FKBP1A) (binding partner it blocks)
Mechanism: Inhibitor of mammalian target of rapamycin (MTOR)
Pathways: PI3K/Akt, mTORC1
Therapy area: Oncology
Developer: Biodexa Pharmaceuticals (BDRX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04230499	Phase 2	Familial Adenomatous Polyposis	Active not recruiting	BDRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Familial Adenomatous Polyposis

Other drugs acting on MTOR

Gedatolisib FDA approved Sirolimus FDA approved CC-115 Phase 2 CERC-006 Phase 1 Samotolisib Phase 2

More from Biodexa Pharmaceuticals

MTX110 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BDRX page.

Follow BDRX, the company behind Encapsulated Rapamycin

See BDRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BDRX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z